Showing 4081-4090 of 7513 results for "".
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in
- Tremfya Shows Improvement in PsA Joint and Skin Symptomshttps://practicaldermatology.com/news/tremfya-shows-improvement-in-psa-joint-and-skin-symptoms/2460412/Tremfya (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA), according to data fr
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomiz
- Sunscreen Tips: Expert Shares Insights on Patient Educationhttps://practicaldermatology.com/news/sunscreen-tips-expert-shares-insights-on-patient-education/2460400/By Naz Saedi, MD A recent survey from the American Academy of Dermatology shows that 76 percent of people think that sunscreen is important but only about 40 percent wear sunscreen. These numbers indicate a significant disconnect; while people understand the concept and the importance o
- May Is Ichthyosis Awareness Monthhttps://practicaldermatology.com/news/may-is-ichthyosis-awareness-month/2460390/May is Ichthyosis Awareness Month, and Timber Pharmaceuticals, LLC is highlighting the efforts of the
- Supportive Oncodermatology Interventions Improve Patient Quality of Lifehttps://practicaldermatology.com/news/supportive-oncodermatology-interventions-improve-patient-quality-of-life-1/2460377/Enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score, according to a recent survey from the George Washington University (GW) Cancer Center. The
- Suneva to Distribute Sinclair Pharma's Silhouette Instalift Sutureshttps://practicaldermatology.com/news/suneva-to-distribute-sinclair-pharmas-silhouette-instalift-sutures/2460372/Suneva Medical, Inc. is the exclusive North American distributor for Sinclair Pharma's Silhouette Instalift sutures "We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio,"
- AAD Survey: Most Americans Know Sun Protection Is Important, Still Don't Protect Themselveshttps://practicaldermatology.com/news/aad-survey-most-americans-know-sun-protection-is-important-but-still-dont-protect-themselves-1/2460367/Fully 76 percent of Americans agree that sun protection is an important healthy habit, yet only 41 percent report regularly protecting themselves outdoors — increasing their risk for skin cancer, according to a new survey from the American Academy of Dermatology. What’s more
- R2 Technologies Receives $10M Second Tranche Investment for CryoAesthetic Technologyhttps://practicaldermatology.com/news/r2-technologies-receives-10m-second-tranche-investment-for-cryoaesthetic-technology/2460361/R2 Technologies Inc. scored $10 million in funding from Huadong Medicine Company Limited to help to commercialize their CryoAesthetic technology, which reduces the appearance of sun damage and uneven skin tone. The CryoAesthetic procedure